China Baoan forecasts first-half loss of up to 37 million yuan; BTR and Mayinglong main businesses still growing steadily

Earnings
โดย 证券时报·Read original
Summary · why it matters

China Baoan has disclosed its first-half 2026 earnings forecast, projecting a loss of approximately 19 million to 37 million yuan. The loss mainly stems from a significant year-on-year decline in gains and losses on trading financial assets held by subsidiaries, as well as investment income accounted for under the equity method. However, based on first-quarter 2026 data disclosed by its two major subsidiaries, BTR and Mayinglong, China Baoan's main business continues to maintain a steady growth trend. BTR achieved first-quarter revenue of 4.31 billion yuan, up 27.09 percent year-on-year, with net profit attributable to the parent of 161 million yuan. Its first-phase 80,000-tonne project in Indonesia has reached full production, the second phase has been successfully commissioned, and the overseas base in Morocco is steadily under construction. BTR has also achieved full coverage of all four major technology routes for silicon-based anodes. Mayinglong reported first-quarter revenue of 1.012 billion yuan and net profit attributable to the parent of 213 million yuan. Sales of its musk hemorrhoid ointment reached 200 million units in 2025, while hemorrhoid suppositories reached 332 million units. Its health business achieved full-year revenue growth of 30 percent and net profit growth of 25 percent in 2025, becoming a new growth engine.

Impact on stocks 3

Others± Mixed · 3 stocks
China Baoan Group Co Ltd
000009
▼ NegativeCapitalrelevance

China Baoan forecasts first-half loss of up to 37 million yuan due to declines in trading financial assets and investment income.

Mayinglong Pharmaceutical Group Co Ltd
600993
▲ PositiveDemandrelevance

Mayinglong reported strong Q1 revenue and profit, with sales of hemorrhoid ointment and suppositories reaching high volumes, and health business growing 30%.

Theme Impact 1

Off-coverage companies 1

贝特瑞新材料集团股份有限公司 (BTR New Material Group)Private▲ Positive
Demandrelevance

BTR reported Q1 revenue up 27% and profit of 161 million yuan, with full production at Indonesia phase 1 and progress on phase 2 and Morocco base.

Related news

3impact 4

US, Denmark and Greenland Reach New Security Agreement, Replacing 1951 Pact

The United States has reached an agreement with Greenland and Denmark that will open the way for the US to permanently expand its military and security role on the island of Greenland, while blocking the influence of adversary nations. The three parties are expected to sign jointly during the United Nations General Assembly in New York next week, and the new agreement will replace the 1951 Greenland Defense Agreement. The US State Department stated that the agreement will prohibit countries that are not members of the North Atlantic Treaty Organization, or NATO, from establishing bases or stationing troops in Greenland, and will also bar non-allied countries from investing in mining and critical minerals. These conditions appear aimed at blocking China or Russia from accessing resources or establishing military footholds in Greenland. President Donald Trump posted a message stressing that the United States will be able to do everything necessary to ensure stability and protect the security of Greenland, as well as that of the United States, and confirmed that this is not a transfer of sovereignty or a cession of territory to the US. Meanwhile, Mette Frederiksen, the Prime Minister of Denmark, and Jens-Frederik Nielsen, the Prime Minister of Greenland, confirmed the agreement through a joint statement, with Frederiksen stating that the agreement will help strengthen security in the Arctic and North Atlantic region, while affirming the sovereignty and territorial integrity of the Kingdom of Denmark, as well as the right of Greenlanders to determine their own future.
Politico·2hRead more →

Albemarle Fair Value Cut 7.8% to US$172.56 as Analysts Reset Lithium Assumptions

Albemarle's fair value estimate has been revised down from US$187.16 to US$172.56, a reduction of about 7.8%, as analysts reset their lithium assumptions. The revision reflects updated modeling assumptions, with revenue growth revised from 7.91% to 5.15%, the net profit margin assumption shifted from 34.27% to 35.74%, the future P/E multiple changed from 11.57x to 10.30x, and the discount rate adjusted from 7.41% to 7.50%. Wall Street targets moved broadly lower: Truist cut its target to US$225 from US$245, Scotiabank trimmed its target to US$190 from US$200 while maintaining an Outperform view, RBC Capital reduced its target to US$166 from US$257 while keeping an Outperform rating, and BofA moved its target to US$155 from US$225. On the bearish side, Morgan Stanley cut its target to US$161 from US$189, Mizuho lowered its target to US$185 from US$205 with a Neutral stance, and JPMorgan reduced its target to US$140 from US$160 while maintaining a Neutral rating after updating its model following the Q2 report.
Simply Wall St·14hRead more →

Albemarle Shares Fall 14.3% as Analysts Cut Earnings Estimates

Albemarle has drawn heightened investor attention after its shares returned -14.3% over the past month, compared with a -1.3% change for the Zacks S&P 500 composite and a 6.3% loss for the Zacks Chemical - Diversified industry. For the current quarter, the company is expected to post earnings of $2.55 per share, a change of +1442.1% from the year-ago quarter, though the Zacks Consensus Estimate has fallen 15.9% over the last 30 days. For the current fiscal year, the consensus earnings estimate of $11.39 points to a change of +1541.8% from the prior year and has declined 4.4% over the past month, while the next fiscal year's estimate of $11.07 indicates a -2.8% change and has slipped 3.9%. The consensus sales estimate of $1.52 billion for the current quarter points to a year-over-year change of +16.1%, with $6.1 billion and $6.35 billion expected for the current and next fiscal years. Albemarle reported revenues of $1.74 billion in the last reported quarter, up 31.1% year over year, with EPS of $3.75 versus $0.11 a year ago, and carries a Zacks Rank #3 (Hold) and a Zacks Value Style Score of B.
Zacks Investment Research·20hRead more →